esomeprazole + domperidone (Ken Pharmaceuticals)

Nexon-RD is a fixed-dose combination pharmaceutical product containing **esomeprazole**, a proton pump inhibitor (PPI), and **domperidone**, a dopamine D2 receptor antagonist. Marketed by Ken Pharmaceuticals, it is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and functional dyspepsia, particularly when symptoms are associated with delayed gastric emptying or nausea. Esomeprazole works by irreversibly inhibiting the H+/K+-ATPase enzyme system (the proton pump) in the gastric parietal cells, thereby reducing gastric acid secretion. Domperidone acts as a prokinetic agent by antagonizing dopamine receptors in the gastrointestinal tract and the chemoreceptor trigger zone, which increases lower esophageal sphincter tone, enhances gastroduodenal motility, and provides antiemetic effects. This combination therapy addresses both the excessive acid production and the motility issues often found in acid-peptic disorders.

Brand names

Nexon-RD

Other names

esomeprazole and domperidone combination